title: Prognostic significance of imaging contrast enhancement for WHO grade II gliomas.
abstract: In this study, we investigated the prognostic value of MRI contrast enhancement (CE) at the time of histological diagnosis specifically in a selected population of WHO grade II gliomas. We reviewed 927 histologically proven WHO grade II gliomas for which contrast-enhanced MR images were available at the time of histological diagnosis. CE patterns were classified into three categories: "patchy and faint," "nodular-like," and "ring-like." CE progression over time was recorded before oncological treatment on successive MR images, when available. CE was present in 143 cases (15.9%), with 93 patchy and faint, 50 nodular-like, and no ring-like patterns. CE areas were time progressive before oncological treatment in 35 of the 56 available cases (62.5%). Regardless of its pattern, the presence of CE was not significantly associated with a worsened prognosis (p = 0.415) by univariate analysis. Only the nodular-like pattern of CE (p < 0.01) and the time-progressive CE (p < 0.001) in the available subgroup proved to be statistically associated with survival since first oncological treatment. The present results show the necessity, in cases of WHO grade II gliomas, to study CE at the time of histological diagnosis and, whenever possible, to follow its progression over time before oncological treatment. Nodular-like CE and time-progressive CE are associated with a worsened prognosis, both suggesting malignant transformation, even though histopathological examination cannot initially disclose signs of malignancy in those areas.
authors.affiliation: Department of Neurosurgery, Hôpital de la Pitié-Salpêtrière, Paris, INSERM U678, Paris, France.
authors.forename: Johan
authors.initials: J
authors.lastname: Pallud
authors.forename: Laurent
authors.initials: L
authors.lastname: Capelle
authors.forename: Luc
authors.initials: L
authors.lastname: Taillandier
authors.forename: Denys
authors.initials: D
authors.lastname: Fontaine
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Mandonnet
authors.forename: Rémy
authors.initials: R
authors.lastname: Guillevin
authors.forename: Luc
authors.initials: L
authors.lastname: Bauchet
authors.forename: Philippe
authors.initials: P
authors.lastname: Peruzzi
authors.forename: Florence
authors.initials: F
authors.lastname: Laigle-Donadey
authors.forename: Michèle
authors.initials: M
authors.lastname: Kujas
authors.forename: Jacques
authors.initials: J
authors.lastname: Guyotat
authors.forename: Marie-Hélène
authors.initials: MH
authors.lastname: Baron
authors.forename: Karima
authors.initials: K
authors.lastname: Mokhtari
authors.forename: Hugues
authors.initials: H
authors.lastname: Duffau
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000175:diagnosis*; D003287:Contrast Media; D005260:Female; D019786:Gadolinium DTPA; D005910:Glioma / Q000175:diagnosis*; D020773:Headache Disorders / Q000175:diagnosis; D006801:Humans; D007089:Image Enhancement; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000175:diagnosis; D011379:Prognosis; D012640:Seizures / Q000175:diagnosis; D015996:Survival Rate; D055815:Young Adult
chemical_list: D003287:Contrast Media; D019786:Gadolinium DTPA